Académique Documents
Professionnel Documents
Culture Documents
Eficacia y Realizado
seguridad en en 52
ms de 10.000 pases
pacientes
Estudio FLAME
INDICE
Material y mtodos:
Resultados:
Objetivo primario
Objetivos secundarios
Seguridad
Conclusiones
Estudio FLAME
Material y mtodos:
Resultados:
Objetivo primario
Objetivos secundarios
Seguridad
Conclusiones
Estudio FLAME
Material y mtodos
Objetivos del estudio
Tipo de medicacin
LAMA
SAMA
Combinacin fija de LABA/CI y CI que no forman parte de esa combinacin
Combinacin fija SABA/SAMA
LABA
SABA
Inhibidores de la fosfodiesterasa IV
Xantinas (cualquier administracin)
Corticoides parenterales u orales
Corticoides intramusculares depot
Diseo del estudio
30-das
Periodo de tratamiento
Periodo de randomizacin seguimiento
(52 semanas) seguridad
Da 35 a Da 28 a Da 1 a Da 365 Da 366 a
Da 29 Da 1 Da 395
Randomizacin
Empeoramiento de 1 sntoma mayor junto con un
aumento de la gravedad de uno de los siguientes
sntomas menores durante al menos dos das
consecutivos: Dolor de garganta, resfriado (rinorrea
y/o congestin nasal), fiebre sin otra causa, tos,
sibilantes
Gravedad de la exacerbacin
es
2 Were lost to follow-up
4942 Entered run-in period
t
1 Was withdrawn by physician
cie n rna
a e
1 Was recorded as discontinued during screening period
3 36 u p o o
83 Withdrew or withdrawn by guardian
n r p
67 Had adverse event
l
3362 Underwent randomization
y n
16 Were unable to use device
in
4 Had technical problems
Se i e n te s 3 Died
p ac c ie
680 p a
1680 Were assigned to IND/GLY group
2
1682 Were assigned to SFC group
1 8
- - 16
5 Were excluded from modified intention- 1680 Received treatment and 3 Were excluded from modified intention-
1678 Received treatment and to-treat and per-protocol analyses were included in safety to-treat and per-protocol analyses
were included in safety 3 Did not receive treatment analysis 1 Did not receive treatment
analysis 1 Was participating in another trial 1 Did not receive treatment 2 Had violation of Good Clinical
3 Did not receive treatment 1 Had violation of Good Clinical 320 Discontinued treatment: Practice guidelines
SFC
278 Discontinued treatment Practice guidelines 145 Had adverse event 123 Were excluded from per-protocol
129 Had adverse event 147 Were excluded from per-protocol 125 Withdrew or were analysis only
111 Withdrew or were analysis only withdrawn by guardian 91 Did not meet inclusion criteria or
withdrawn by guardian 99 Did not meet the inclusion criteria 22 Had lack of efficacy met exclusion criteria
17 Had lack of efficacy or met the exclusion criteria 16 Were withdrawn by 32 Received prohibited medication
13 Were withdrawn by 45 Received prohibited medication physician 8 Had treatment deviation
physician 9 Had treatment deviation 7 Had protocol deviation
8 Had protocol deviation 1 Had other reason 5 Had technical problems
1400 Completed 52 wk 1675 Were included in modified 1360 Completed 52 wk 1679 Were included in modified
of treatment intention-to-treat analysis of treatment intention-to-treat analysis
1528 Were included in per-protocol 1556 Were included in per-protocol
analysis analysis
Nmero de pacientes que
discontinuaron
el tratamiento con CI durante el
periodo de seleccin
I n o
o s C
d e l ro de
s ca m e
b ru n
a da y or s
ti r m a n e
a re u n a c io
L l i c a e rb
imp c
exa
Caractersticas basales de los
pacientes
SFC
XOTERNA 50/500 g
110/50 g 2
1vez/da veces/da Total
(N=1680) (N=1682) (N=3362)
Edad 64.6 (7.9) 64.5 (7.7) 64.6 (7.8)
Sexo no. (%) 1299 (77.3) 1258 (74.8) 2557 (76.1)
Duracin de la EPOC-aos 7.2 (5.3) 7.3 (5.5) 7.3 (5.4)
Uso de CI durante periodo de selecccin no. (%) 954 (56.8) 939 (55.8) 1893 (56.3)
Uso de LAMA durante periodo de selecccin no. 1008 (60.0) 1029 (61.2) 2037 (60.6)
(%)
Uso de LABA durante periodo de selecccin no. 1129 (67.2) 1128 (67.1) 2257 (67.1)
(%)
Fumadores actuales no. (%) 664 (39.5) 669 (39.8) 1333 (39.6)
Gravedad de la EPOC no. (%)
Grupo A 2 (0.1) 0 2 (0.1)
Grupo B 400 (23.8) 422 (25.1) 822 (24.4)
Grupo C 1 (0.1) 2 (0.1) 3 (0.1)
Grupo D 1265 (75.3) 1249 (74.3) 2514 (74.8)
Limitacin del flujo areo no. (%)
GOLD 1 0 0 0
GOLD 2 560 (33.3) 563 (33.5) 1123 (33.4)
GOLD 3 973 (57.9) 981 (58.3) 1954 (58.1)
GOLD 4 133 (7.9) 124 (7.4) 257 (7.6)
INDICE
Material y mtodos:
Resultados:
Objetivo primario
Objetivos secundarios
Seguridad
Conclusiones
Estudio FLAME
Resultados
Objetivo primario
Margen de Margen de no
superioridad inferioridad
5.0
Todas las exacerbaciones (tasa anual)
RR (95% CI)
0.89 (0.83, 0.96), P=0.003
3.0
2.0
0
Objetivo secundario
1.0
(tasa anual)
0.75
0.5
SFC 50/500 g (N=1656)
XOTERNA 110/50 (N=1651)
0.25
1.19 0.98
0
Nmero de eventos: Xoterna = 1,265 (includos los 209 graves)
SFC = 1,452 (includos los 241 graves)
Objetivo secundario
RR (95% CI)
0.20 0.87 (0.69, 1.09), P=0.231
13% reduccin
numrica
0.15
0.10
0.17 0.15
0
Nmero de eventos: Xoterna = 209
SFC = 241
Xoterna prolong en el tiempo hasta la primera exacerbacin en
cualquier tipo de exacerbaciones
100 Todas
SFC 50/500 g Hazard ratio, 0.84
90 XOTERNA 110/50 g
Probabilidad de exacerbaciones (%)
0
0 6 12 19 26 32 38 45 52
Pacientes de riesgo Semanas
no. de pacientes
Exacerbaciones en el ao
1 exacerbacin 1329 1335 0.87 (0.81, 0.95)
previo
2
321 320 0.89 (0.76, 1.05)
exacerbaciones
Uso de CI durante el
No uso de CI 710 729 0.88 (0.79, 0.98)
periodo de seleccin
no. de pacientes
no. de pacientes
no. de pacientes
Fumador durante periodo seleccin Ex-fumador 1004 998 0.84 (0.74, 0.95)
Gravedad del flujo areo Moderada 557 557 0.81 (0.68, 0.97)
100
=110 mL, P<0.001
75
FEV1 AUC012h (mL)
50
25
78
0 -32
50
Objetivo secundario: Calidad de vida
50
45
Porcentaje de pacientes con
40
49.2% 43.7%
35
30
25
puntuacin 4
20
15 SFC 50/500 g
10 XOTERNA 110/50 g
5
0
(P<0.001)
Objetivo secundario: Medicacin de
rescate
Xoterna disminuy el uso de medicacin de rescate vs SFC durante 52
semanas
0 -0.76 -1.01
0.25
Uso de medicacin de rescate
0.50
0.75
1.0
=0.25, P<0.001
1.25 SFC 50/500 g b.i.d. (N=1624)
IND/GLY 110/50 g q.d. (N=1609)
1.5
Objetivo secundario: Seguridad
Nmero (porcentaje)
Pacientes con 1 acontecimiento adverso 1459 (86.9) 1498 (89.2)
Acontecimientos adversos que se produjeron en 3% :
Empeoramiento EPOC 1299 (77.4) 1374 (81.8)
Nasofaringitis 197 (11.7) 195 (11.6)
Infecciones vricas tracto respiratorio superior 132 (7.9) 138 (8.2)
Infecciones bacterianas tracto respiratorio superior 125 (7.4) 168 (10.0)
Infecciones tracto respiratorio inferior 82 (4.9) 98 (5.8)
Infecciones tracto respiratorio superior 81 (4.8) 83 (4.9)
Neumona 53 (3.2) 80 (4.8)*
Tos 50 (3.0) 51 (3.0)
Disnea 49 (2.9) 51 (3.0)
Candidiasis oral 20 (1.2) 71 (4.2)
Acontecimientos adversos graves 308 (18.4) 334 (19.9)
Muertes 24 (1.4) 24 (1.4)
Pacientes que discontinuaron por acontecimiento adverso 126 (7.5) 143 (8.5)
Pacientes que discontinuaron por acontecimiento adverso 85 (5.1) 87 (5.2)
grave
INDICE
Material y mtodos:
Resultados:
Objetivo primario
Objetivos secundarios
Seguridad
Conclusiones
Conclusiones
XOTERNA